ASTRO 2022 | Results from a Phase III study of sorafenib and SBRT for hepatocellular carcinoma

Laura A. Dawson, MD, FASTRO, Princess Margaret Cancer Center, Toronto, Canada, discusses results of the randomized Phase III study (NCT01730937) investigating the use of stereotactic body radiation therapy (SBRT) alongside sorafenib in patients with unresectable hepatocellular carcinoma (HCC). The study found clinically significant improvements in patients treated with SBRT alongside sorafenib compared to sorafenib alone for all end points. The median overall survival (OS) rate increased from 12 months to 16 months. Notably, OS rate increased more prevalently in patients with advanced HCC, from 8.8 months to 28.4 months. Median progression-free survival (PFS) improved from 5.5 months to 9.2 months, and median time to progression improved from 9.5 months to 18.5 months. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.